Kybernin P (Antithrombin Iii)

Kybernin P is an antithrombotic agent used in conditions related to antithrombin deficiency and thrombosis risk.

• Hereditary antithrombin deficiency: provides replacement therapy to restore normal anticoagulant activity.
• Surgical patients at risk of thrombosis: helps prevent peri‑operative thromboembolic complications.
• Acquired antithrombin deficiency (e.g., severe sepsis): supports anticoagulation to reduce clot formation.

• Kybernin P contains recombinant antithrombin III, which binds to and accelerates the inhibition of thrombin (factor IIa) and factor Xa. By enhancing these natural anticoagulant pathways, the product restores physiological regulation of coagulation in individuals lacking sufficient antithrombin, thereby reducing the generation of fibrin clots.

Kybernin P may be associated with adverse reactions typical of intravenous protein therapeutics.

Common Side Effects

• Injection site erythema: mild redness at the infusion site.
• Fever: transient elevation of body temperature.
• Headache: mild to moderate headache.
• Nausea: occasional feeling of nausea.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Thrombotic microangiopathy: rare clotting disorder.
• Hemolysis: destruction of red blood cells.
• Hepatic enzyme elevation: abnormal liver function tests.

Before using Kybernin P, clinicians should consider several safety precautions to minimize risks.

• Assess antithrombin levels: confirm deficiency before initiating therapy.
• Monitor coagulation parameters: regularly check activated partial thromboplastin time (aPTT) and anti‑Xa activity.
• Evaluate for hypersensitivity: discontinue if signs of allergic reaction appear.
• Adjust dose in renal impairment: consider reduced dosing in patients with severe kidney dysfunction.
• Avoid concomitant pro‑coagulant agents: limit use with drugs that increase clotting risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other medications that affect hemostasis or protein metabolism.

Major Interactions (Avoid)

• Heparin: combined use may cause excessive anticoagulation.
• Direct oral anticoagulants (e.g., rivaroxaban, apixaban): increased bleeding risk.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding.
• ACE inhibitors: may potentiate hypotensive effects during infusion.
• Immunosuppressants (e.g., cyclosporine): possible altered clearance.
• Concomitant plasma protein binders: may affect drug distribution.